海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Effects of new longacting insulin analogs on metabolic control, endogenous insulin production, GH/IGF-I axis and quality of life – comparison of NPH, glargine och detemir insulin from the debut of T1DM in adolescents - Basal analog study
- Type 1 Diabetes Mellitus (T1DM)
- Sweden
- 2005-06-17
Authorised
- A randomised controlled study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetes. - n/a
- Type 1 Diabetes Mellitus
- United Kingdom
- 2006-02-06
Authorised
- Comparison of the effect of insulin detemir and NPH insulin on dawn phenomenon in patients with Type 1 diabetes An open-labelled, randomised, cross-over, multi-center trial comparing the effect of insulin detemir versus NPH insulin as basal insulins on dawn phenomenon and the glycaemic control in patients with Type 1 diabetes treated on a basal-bolus regimen - Dawn phenomenon – insulin detemir
- Type 1 diabetes mellitus, dawn phenomenon
- Hungary
- 2006-01-25
Authorised
- A study to investigate the effects of the course of first-line therapy with gemcitabine on the success of second-line therapy with NAL-IRI combination therapy
- locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment MedDRA version: 20.0 Level: LLT Classification code 10033604 Term: Pancreatic cancer System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033607 Term: Pancreatic cancer recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2017-10-09
Authorised
- Arginine as medication to improve outcome in patients with galactosemia
- Classic galactosemia;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Netherlands
- 2017-09-13
Authorised
- A multicenter randomized phase 2 study to compare the efficacy and safety of avelumab versus standard second line treatment, in patients with metastatic colorectal cancer (MMR) after first line treatment progression.
- COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI);Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2017-07-12
Authorised
- FOLFIRI + panitumumab in second-line in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line
- Subjects treated in first-line with panitumumab and FOLFOX and having at least achieved stable disease with wild type RAS metastatic Colorectal Cancer confirmed in liquid biopsies before starting second line treatment will be screened for this trial. Only subjects who have interrupted panitumumab for MedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2018-04-09
Authorised
- ENSAYO PILOTO CON IMATINIB PARA PACIENTES CON NEUROFIBROMA PLEXIFORME ASOCIADO A LA NEUROFIBROMATOSIS TIPO I. PILOT STUDY WITH IMATINIB FOR PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE I PATIENTS
- Tratamiento de los neurofibromas plexiformes de alto riesgo no abordables quirúrgicamente en pacientes con neurofibromatosis tipo I
- Spain
- 2009-11-19
Authorised
- [Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus] Target-specific therapy of metastatic urothelial carcinoma with temsirolimus - Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus
- Chemotherapy refractory metastatic urothelia carcinoma MedDRA version: 9.1 Level: LLT Classification code 10064467 Term: Urothelial carcinoma
- Germany
- 2009-01-20
Authorised
- AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB - BEBYP
- METASTATIC COLORECTAL CANCER PATIENTS MedDRA version: 9.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastatic
- Italy
- 2008-02-06